Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1846 to 1860 of 2172 results for technology appraisal

  1. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]

    In development Reference number: GID-TA11589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development Reference number: GID-TA11475 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    In development Reference number: GID-TA11367 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]

    In development Reference number: GID-TA11664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    In development Reference number: GID-TA11645 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    In development Reference number: GID-TA11647 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    In development Reference number: GID-TA11128 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    Discontinued Reference number: GID-TA11655

    Technology appraisal guidance
    Discontinued

  11. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development Reference number: GID-TA10779 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development Reference number: GID-TA11344 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development Reference number: GID-TA11228 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued Reference number: GID-TA10233

    Technology appraisal guidance
    Discontinued

  15. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued